Cite
HARVARD Citation
Tanaka, Y. et al. (2021). Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD open. 7 (2), p. . [Online].